Clinical Trial Update: Docetaxel and Carboplatin for Patients With mCRPC and DNA-Repair Deficiencies [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating docetaxel and carboplatin in metastatic castration-resistant prostate cancer with DNA-repair deficiencies was terminated; results poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hormone-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: Seattle Institute for Biomedical and Clinical Research | Conditions: Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2021-08-05